Year：All Category：All RSS
02.05.2026
Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 (IFRS)
01.09.2026
Launch of Aflibercept kit for IVT inj. 40 mg/mL Bayer
12.23.2025
Santen Launches Verkazia® (Ciclosporin Eye Drops (III) ) in China For the Treatment of Severe Vernal Keratoconjunctivitis (VKC) in Children and Young Adults
12.22.2025
Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis
12.05.2025
Aflibercept intraocular injection kit 40 mg/mL Bayer Listed in NHI Drug Price List
12.03.2025
Santen and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases
11.20.2025
On December 1, Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”
11.06.2025
Santen Announces Cancellation of Treasury Shares
11.06.2025
Santen Announces Completion of Share Buyback
11.06.2025
Summary of Consolidated Financial Results for the Six Months Ended September 30, 2025 (IFRS)
11.04.2025
Santen Announces Status of Share Buyback
10.31.2025
Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
10.23.2025
Santen Launches SETANEO® Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension
10.20.2025
Santen Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea
10.16.2025
Announcement Regarding the Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”
10.14.2025
Santen Launches Global Employee Volunteer Initiative on World Sight Day — Responding to 167 Calls from Visually Impaired Individuals in 26 Languages via the Be My Eyes App —
10.01.2025
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
10.01.2025
Santen Announces Status of Share Buyback
09.30.2025
Santen and RemeGen Announce Biologic License Application (BLA) Acceptance for RC28-E Intravitreal Injection in Diabetic Macular Edema in China
09.25.2025
Santen Publishes its Annual Integrated Report “Santen Report 2025”
